Clinical Trials

AFT-47 ARACOG

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

Objective

This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic or non-metastatic CRPC (mCRPC or M0CRPC) treated with darolutamide or enzalutamide.

NCT#04335682

Clinical Trial Categories

  • Prostate Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at (603) 224-2556

Location

  • Payson Center for Cancer Care
    Concord Hospital
    250 Pleasant Street
    Concord, NH 03301
    Main: (603) 230-6000